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Abstract Recent evidence suggests that the GABA
transporter 1 (GAT-1; SLC6A1) plays a role in the path-
ophysiology and treatment of anxiety disorders. In order to
understand the impact of genetic variation within SLC6A1
on pathological anxiety, we performed a case–control
association study with anxiety disorder patients with and
without syndromal panic attacks. Using the method of
sequential addition of cases, we found that polymorphisms
in the 50 ﬂanking region of SLC6A1 are highly associated
with anxiety disorders when considering the severity of
syndromal panic attacks as phenotype covariate. Analysing
the effect size of the association, we observed a constant
increase in the odds ratio for disease susceptibility with an
increase in panic severity (OR * 2.5 in severely affected
patients). Nominally signiﬁcant association effects were
observed considering the entire patient sample. These data
indicate a high load of genetic variance within SLC6A1 on
pathological anxiety and highlight GAT-1 as a promising
target for treatment of anxiety disorders with panic
symptoms.
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Introduction
Anxiety disorders are frequent psychiatric conditions in the
general population with lifetime prevalence rates ranging
from 13.6 up to 28.8% (Alonso et al. 2004; Kessler et al.
2005a). Due to high comorbidity rates with other psychi-
atric disorders and physical illness (e.g., Kessler et al.
2005b; Mayer et al. 2001; Merikangas et al. 2003) quality
of life is seriously compromised and social disadvantage
often arises resulting in impairment comparable to chronic
somatic disorders.
A great number of studies have been carried out inves-
tigating the inﬂuence of genetic and environmental
underpinnings of pathological anxiety. So far, epidemio-
logical evidence suggests a familial aggregation of anxiety
disorders (e.g., Horwath et al. 1995; Low et al. 2008;
Nocon et al. 2007) which is highly attributable to genetic
factors with heritability estimates around 30% (e.g.,
Hettema et al. 2005). The understanding of the genetic
mechanisms that contribute to development or maintenance
of anxiety disorders may offer new insights in the patho-
physiology of these disorders and potentially novel
therapeutic strategies.
Several lines of preclinical and clinical evidence support
the view that the c-aminobutyric acid (GABA) system is a
major candidate in the pathogenesis of anxiety, fear and
related psychopathological conditions. It has been shown
that pentylenetetrazole, an agent antagonizing GABAA
receptor function, induces symptoms of anxiety, ﬂash
backs of traumatic memories and strong avoidance
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augmentation of brain GABA function by positive allo-
steric modulators of GABAA receptors, e.g., using
benzodiazepines, promotes rapid and profound anxiolysis
in patients suffering from affective and anxiety disorders
(Kalueff and Nutt 2007; Nemeroff 2003). Apart from
pharmacological agents modulating the GABAA receptor, a
novel class of drugs (initially developed as antiepileptic
medication) targeting synaptic transport or metabolism of
GABA has emerged in the clinical management of anxiety
states (Rogawski and Loescher 2004; Zwanzger and
Rupprecht 2005).
Among them, drugs have been developed that act by
blockade of GABA transporters (GAT), thereby inhibiting
GABA uptake from the synaptic cleft. Four subtypes of
GATs, GAT-1, GAT-2, GAT-3 and Betaine/GABA trans-
porter 1 (BGT-1) have been identiﬁed. GAT-1 constitutes
the main neuronal transporter isoform that is abundantly
expressed on presynaptic GABAergic terminals of neurons
and on glial cells (Dalby 2003; Sarup et al. 2003). The ﬁrst
(and only) selective inhibitor of GAT-1 sites in clinical use
is tiagabine. It has been approved for add-on therapy of
partial-onset seizures in adults (LaRoche and Helmers
2004). In addition, several preliminary studies report that
tiagabine is effective in psychiatric diseases such as panic
disorder, generalized anxiety disorder, posttraumatic stress
disorder, in which augmentation of brain GABA neuro-
transmission is thought to alleviate clinical symptoms
(Carpenter et al. 2006; Connor et al. 2006; Pollack et al.
2005; Rosenthal 2003; Sheehan et al. 2007; Zwanzger et al.
2001).
In addition to the clinical beneﬁts and relevance
observed by psychotropic GAT-1 blockade in anxiety
disorder patients, neurobiological evidence for aberrant
GABAergic neuroinhibitory processes on the level of
GABA release and reuptake comes from neuroimaging
studies. Using magnetic resonance spectroscopy technique,
lower levels of GABA in cortical areas and the basal
ganglia of panic disorder patients (Goddard et al. 2001;
Ham et al. 2007) and in the thalamus of patients suffering
from social anxiety disorder (Pollack et al. 2008) as com-
pared to healthy control subjects have been documented. In
a preliminary follow-up analysis, Goddard et al. (2004a)
report that the low cortical GABA levels in panic disorder
patients is largely determined by familial and, possibly,
genetic factors.
As a consequence, the SLC6A1 gene, which encodes the
GAT-1 protein, can be considered an obvious candidate
gene for human gene association studies investigating the
genetic liability to anxiety disorders. In the present study,
we performed a case–control association study investigat-
ing the genetic variance in SLC6A1 in anxiety disorder
patients with syndromal panic attacks and matched control
subjects. We focused on this phenotype due to the high
frequency of panic attacks in anxiety disorder patients and
good clinical response to drugs that enhance GABAergic
neurotransmission.
Methods
Study population
The present study was approved by the local ethics com-
mittee. Written informed consent was obtained from all
participating subjects.
The study included 238 adult patients consecutively
recruited from the Anxiety Disorders Outpatient Clinic of
the Max Planck Institute of Psychiatry in Munich pre-
senting with the following anxiety disorders: panic disorder
with agoraphobia (71.4%), panic disorder without agora-
phobia (13.0%), agoraphobia (1.7%), social phobia (7.6%),
speciﬁc phobia (3.8%) and generalized anxiety disorder
(2.5%). Demographic and clinical data are shown in
Table 1. Patients were diagnosed by trained psychiatrists
using the structured clinical interview (SCID) for DSM-IV
(Wittchen et al. 1997). All patients underwent a thorough
medical examination including EEG, ECG and detailed
hormone laboratory assessment. Anxiety disorders due to a
medical or neurological condition or a comorbid Axis II
disorder were exclusion criteria.
Table 1 Demographic and clinical characteristics of the study
population
Patients Controls
Total N = 505
N 238 (47.1%) 267 (52.9)
Sex
Male (%) 37.8 39.2
Female (%) 62.2 60.7
Age (SD) (years) 38.2 (11.6) 38.5 (11.6)
Age of onset (SD) (years) 27.4 (11.2)
PAS total (SD) 29.8 (9.8)
Panic attacks (SD) 6.5 (3.1)
Agoraphobia (SD) 6.8 (3.1)
Anticipatory anxiety (SD) 5.8 (1.7)
Disability (SD) 6.1 (2.8)
Health concerns (SD) 4.4 (2.5)
Quantitative analysis of severity of panic and anxiety symptoms using
the panic and agoraphobia scale. Data are shown as the mean of the
total panic and agoraphobia scale (PAS) score, the mean severity of
panic attacks, phobic avoidance (agoraphobia), anticipatory anxiety,
impairment of social relationships and work (disability) and
assumption of somatic disease (health concerns). SD standard
deviation
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naire asking for nationality, language and ethnicity of the
subject, his/her parents and grandparents. All included
patients were Caucasians with 83% being of German and
17% of other European origin. Patients with Turkish,
Oriental Asiatic and African origin were excluded from the
analysis.
A total of 267 healthy control subjects matched for
ethnicity (using the same questionnaire as for patients),
gender and age were recruited at the Max Planck Institute
of Psychiatry (Table 1). They were randomly selected from
a Munich-based community sample and screened for the
presence of mood disorder, anxiety disorders including
OCD and PTSD, somatoform disorder, alcohol depen-
dence, drug abuse, psychotic disorder, dissociative disorder
NOS and eating disorder using a standardized diagnostic
interview (DSM-IV M-CIDI) (Wittchen 1994; Wittchen
and Pﬁster 1997). Only individuals with a negative life-
time history for these disorders were enrolled in the study.
Assessment of dimensional measures of panic and
anxiety
We used the panic and agoraphobia scale (PAS) (Bandelow
1995) to assess the severity of the worst period of anxiety
and panic symptoms and to further investigate associations
with genetic polymorphisms in the GAT-1 gene. The total
score on this scale revealed a moderate to high severity of
panic and agoraphobia [mean score physician rating (SD):
29.8 (9.8)]. The sub-scores of PAS regarding the severity
of panic attacks, phobic avoidance, anticipatory anxiety,
impairment of social relationships and work as well as
assumption of somatic disease are presented in Table 1.
Ratings were performed by trained psychiatrists.
Psychopathological phenotyping of patients with the
Hamilton Anxiety Scale revealed a mean score of 24.7 (SD
9.8), and the mean Hamilton Depression Scale score was
13.7 (SD 6.6) indicating moderate anxiety and low
depression in these patients (Hamilton 1959, 1960).
DNA preparation, SNP selection and genotyping
On enrolment in the study, up to 40 ml of EDTA blood was
drawn from each subject and DNA was extracted using a
standardized procedure (Puregene whole blood DNA-
extraction kit; Gentra Systems Inc., USA).
For the present study, SNPs were selected from the
Illumina Sentrix Human-1 Genotyping 300K BeadChip
system (Illumina Inc., San Diego, USA) and mapped to the
coding region and in the ﬂanking sequence [n = 20; 15 kb
up- and downstream; from position 10997825 to 11055168
(hg18)] of the GAT-1 gene [SLC6A1 (NM_003042)] on
chromosome 3p25.3 (Fig. 1). SNP genotyping of a total
number of 20 SNPs (average inter-polymorphism distance
3.2 kb) was performed at the Center for Applied Geno-
Typing, CAGT, at the Max Planck Institute of Psychiatry,
Munich, Germany, using the Illumina InﬁniumII technol-
ogy and the protocols provided by the manufacturer.
Genotype calling was according to the manufacturer’s
instructions. Cluster ﬁles for all SNPs were inspected by
eye, and all intensities clustered well into the three
canonical groups. The call rate for each SNP was[99.6%
(mean 99.9%), and minor allele frequencies exceeded 6%.
The reproduction error rate was below 0.0003% as judged
from repeated genotyping of ﬁve samples. Genotype
datasets were checked for identical samples and relatedness
(no identical samples were found). No SNP showed a
signiﬁcant deviation (P \ 0.05) from Hardy–Weinberg
equilibrium (Electronic supplementary material, Table 3).
Data analysis and statistics
All statistical analyses were performed using the WG-
Permer software, a tool for rapid analysis of large scale
genome association studies (http://www.wg-permer.org).
The association analysis for SNPs and phenotypes was
conducted by v
2 tests applying an allelic model. This
approach corresponds to the Armitage test of trend. As the
individual tests are correlated, we used 100.000 permuta-
tions to adjust for multiple testing, namely the minimum
P method of Westfall and Young (1993).
Second, we carried out the Fisher product method for
combining tests (Fisher 1932) to get overall signiﬁcance
levels for the whole set of polymorphisms within the
candidate region. Again, the signiﬁcance of combined tests
was evaluated using permutation (Binder et al. 2004).
For the analysis of linkage disequilibrium (LD) and
haplotype block delineation we used haplotypes estimated
by HAPLOVIEW 4.0 (http://www.broad.mit.edu/mpg/
haploview). Blocks were deﬁned using the conﬁdence
interval method described by Gabriel et al. (2002).
The level of signiﬁcance for all statistical analyses was
set to 5%.
Results
A total number of 20 SNPs were genotyped within the
SLC6A1 locus and ﬂanking regions with all polymor-
phisms passing quality control (see ‘‘Methods’’), and they
were thus included in the statistical analysis.
To test for the effects of population stratiﬁcation, we
applied the method of genomic controls (Binder et al.
2004; Devlin and Roeder 1999) for the data obtained from
the Illumina 300K chip. Thereby, we calculated the allelic
deviation between cases and controls using the v
2 statistics
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123and compared the distribution of the obtained with the
theoretically expected v
2 values. k, the ratio of the median
of the test statistics and the median of the theoretical dis-
tribution was 1.025 indicating almost no population
stratiﬁcation between our study samples.
Case–control analysis
In a ﬁrst analysis of putative associations between anxiety
disorders and genetic variability in SLC6A1, we tested for
case–control differences in the distribution of alleles using a
permutation-based correction (100.000 permutations) as
implemented in the WG-Permer software (see Fig. 1). We
found ﬁve polymorphisms of SLC6A1 to be nominally
associated with the disease (P\0.05: rs956053, rs2697153,
rs2930152, rs1710879, rs2601126). Highest nominal
case–control associations (P\0.026) are listed in Table 2.
Adjustment for multiple testing, however, revealed that
none of them remained signiﬁcantly associated (rs2930152:
P = 0.202; rs2697153: P = 0.238; rs956053: P = 0.321).
Fisher product combined gene-wide testing with 100.000
permutations yielded a P value of 0.03151. Despite only
nominally association effects obtained for single SNPs, the
results of a signiﬁcant combined effect of all investigated
polymorphisms as revealed by Fisher product testing
strongly suggest a major role of SLC6A1 in the genetic
susceptibility of pathological anxiety.
Analysis by sequential addition of cases
We then re-investigated these case–control associations
using the method of sequential addition of cases (ordered
Fig. 1 Illustration and mapping of case–control P values (nominal) for genotyped SNPs at the SLC6A1 locus (upper graph). Lower triangular
graph illustrates linkage disequilibrium (LD) and block structure within the GAT-1 gene using D0 as a measure for LD
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123subset analysis) as proposed by Macgregor et al. (2006).
For this purpose, we ordered patients according to the
severity of syndromal panic attacks using the subscale
‘‘severity of panic attacks’’ of the panic and agoraphobia
scale (PAS). We then created six subsets of patients
(Table 3). Subset I included all study patients with valid
PAS entries (scoring from 0 to 12 on this psychopathology
scale). For subsets II–VI, patients with the least severity of
panic attacks were removed sequentially according to the
cut-off scores detailed in Table 3. In subset VI, only cases
with most severe syndromal panic attacks were included.
We then performed case–control associations sequentially
for each subgroup. We detected the most signiﬁcant asso-
ciations of SLC6A1 polymorphisms when we compared
patients in subset V (PAS C 8) with controls (Fig. 2a). The
highest nominal associations were found for rs2930152 (P
= 9.71e-5) and for rs2697153 (P = 0.000119) which both
withstood permutation-based correction for multiple testing
for all tested SNPs (n = 20) and phenotypes (n =6 )
(rs2930152: P = 0.0083 and rs2697153: P = 0.0101). For
these two SNPs, we observed a constant increase of the
disease odds ratio (OR) with the increase in panic severity,
as illustrated in Fig. 2b. While highest associations were
found with subset V, we observed an even higher disease
OR at both loci for subset VI (i.e., most severely affected
Table 2 Association of GAT-1 single nucleotide polymorphisms with anxiety disorders
SNPs Patients Controls P value
rs2930152 AA, 18.1; AG, 50.4; GG, 31.5 AA, 13.9; AG, 43.8; GG, 48.7 0.0147
rs2697153 AA, 35.7; AG, 48.3; GG, 16.0 AA, 46.8; AG, 40.4; GG, 12.8 0.0181
rs956053 CC, 54.6; CT, 41.2; TT, 4.2 CC, 50.6; CT, 36.7; TT, 12.7 0.0263
The three SNPs showing the lowest nominal P values. Presentation of genotype distributions (%) between anxiety disorder patients and controls;
v
2 tests using the allelic model
Table 3 Classiﬁcation of anxiety disorder patients according to the
severity of syndromal panic attacks
Subsets PA severity Patients (N)
I 0–12 238
II 3–12 198
III 6–12 143
IV 7–12 97
V 8–12 60
VI 9–12 33
A severity index of 0 indicates absence of panic attacks (PA), an
index of 12 the most severe form of syndromal panic
Fig. 2 Sequential analysis of
patient subsets versus controls.
Illustration of nominal P values
for all genotyped SNPs in the
genomic order as presented for
the analysis of patient subset V
versus controls (a). Constant
increases of the odds ratio (OR)
along clusters for rs2930152
and rs2697153; dotted lines
assign upper and lower
conﬁdence intervals of 95% (b).
Distribution of alleles (%) of
rs2930152 and rs2697153
within anxiety disorder patients
of subset V (n = 60; black bars)
and controls (n = 267; white
bars); numbers indicate the total
number of alleles in each
group (c)
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reduces the power to detect signiﬁcant case–control asso-
ciations [cf. increase of 95% conﬁdence interval (CI);
Fig. 2b).
The strong case–control association of rs2930152 with
subset V of our patient sample is reﬂected by an over-
representation of the G-allele in healthy controls with an
OR of 2.20 (CI: 1.47–3.27), thus exerting a protective
effect. Likewise, the A-allele is signiﬁcantly more pre-
valent in controls at the rs2697153 locus (Fig. 2c). The
protective effect of this allele has an OR of 2.17 (CI: 1.46–
3.24). When comparing the distribution of alleles within
cases and controls across patient subsets, we observed the
under-representation of the G-allele at rs2930152 and of
the A-allele at rs2697153 locus in every patient subset
compared to controls with decreasing prevalence along
increases in anxiety severity [rs2930152 G-allele frequen-
cies: 64.2% (controls), 56.7% (subset I), 55.8% (II), 53.5%
(III), 50.5% (IV), 45.0% (V), 42.4% (VI); rs2697153 A-
allele frequencies: 67.0% (controls), 59.9% (subset I),
58.6% (II), 56.3% (III), 52.6% (IV), 48.3% (V), 47.0%
(VI)].
We further calculated a Fisher product combined gene-
wide signiﬁcance applying 100.000 permutations for cases
of subset V versus controls and detected a P value of
0.00013, withstanding even Bonferroni correction for all
performed tests (P = 0.0156). A list of all data for the
genetic associations with all genotyped SNPs across the
patients’ subsets including the results for Fisher product
combined testing is available online (Electronic supple-
mentary material, Tables 1 and 2).
Discussion
In our candidate gene association study we provide ﬁrst
evidence of a possible association of speciﬁc genetic
variants within the SLC6A1 locus encoding GAT-1 with
anxiety disorders with syndromal panic attacks. Further-
more, two SNPs located in the 50 region of this gene
showed an increasing strength of association when patients
were stratiﬁed according to the severity of panic symptoms,
suggesting that our association results may be more spe-
ciﬁc for the development and severity of panic attacks than
anxiety disorders per se.
Panic attacks are circumscribed episodes of severe state
anxiety lasting minutes to hours with escalating symptoms.
While panic attacks are the hallmark of panic disorder, they
also occur regularly in association with other anxiety dis-
orders such as, e.g., social phobia or speciﬁc phobia.
When we ordered patients according to the increase in
panic symptom severity, the two SNPs rs2930152 and
rs2697153, which are in strong LD (r
2 = 1), showed a
substantial increase in the strength of case–control associ-
ations. The disease OR of each SNP at different subsets
displayed a constant increase reaching a value of almost
2.5 when limiting the case groups to patients with severe
panic attacks (PAS [ 8). This suggests that the reported
ﬁnding represents an association with a speciﬁc symptom
of anxiety disorders (i.e., panic attacks) rather than with a
DSM-IV based diagnosis and displays a higher OR than
observed in classical case–control association studies with
complex psychiatric disorders (Lohmueller et al. 2003).
With respect to a possible functional relevance of these
SNPs we would like to note that both polymorphisms are
located in the 50 ﬂanking region of SLC6A1 with some
distance (10 kb) from exon 1 of our candidate gene and
putative promoter regions as predicted by the ElDorado
software (data not shown; www.genomatix.de). At this
point, however, we cannot rule out that these SNPs tag
another more causally related genetic variant. The LD
block that contains these two SNPs stretches from exon 1
to at least 11 kb upstream of the 50 end of the gene (data
according to LD mapping in our study sample), therefore
including the potential 50 promoter region (see Fig. 1). This
block, however, ends before the 50 neighbouring gene
SLC6A11 as shown in the International HapMap Project
data (www.hapmap.org) suggesting that the observed
association with pathological anxiety does indeed represent
an association with the SLC6A1 locus.
While awaiting replication in independent samples, our
data may further highlight the major role of the GAB-
Aergic system in anxiety disorders and, especially, in the
panic phenotype.
Current clinical and preclinical studies support our
evidence that genetic variants in the gene encoding GAT-1
could play an important role in the pathogenesis of path-
ological anxiety states. Recent human studies suggest that
tiagabine, a selective blocker of GAT-1, possesses anxio-
lytic properties in a variety of anxiety disorders (for review
see Schwartz and Nihalani 2006). Another line of evidence
for an involvement of GABA transport, the main regulator
of extracellular GABA, comes from magnetic resonance
spectroscopy studies in anxiety disorder patients which
revealed a signiﬁcant reduction of GABA concentrations in
several brain areas highly relevant in emotion and behav-
iour (Goddard et al. 2001; Ham et al. 2007; Pollack et al.
2008). It has been suggested that these reductions resemble
a trait-like abnormality and might be inﬂuenced by familial
factors (Goddard et al. 2004a, 2004b). Furthermore, using
segregation analyses in families with affective disorders,
Petty et al. (1999) report that plasma membrane GABA
levels are genetically controlled, probably through auto-
somal recessive transmission. Using preclinical models of
anxiety, the pharmacological inhibition of GAT-1 in rats
has been shown to exert anxiolytic-like actions (Schmitt
654 C. K. Thoeringer et al.
123and Hiemke 1999; Schmitt et al. 2002). Likewise, mice
deﬁcient of the GAT-1 gene display lower levels of anxi-
ety-like behaviours in comparison to wild-type animals
(Liu et al. 2007). Using another genetic knock-out (KO)
approach of GAT-1, Chiu et al. (2005) observed a large
gene-dose effect on the behavioural performance of KO
mice. Importantly, this ﬁnding implicates that even subtle
changes in the expression or function due to genetic
modiﬁcations of GAT-1 within the CNS may have a strong
impact on emotional behaviours such as fear and anxiety.
The polygenic model for the genetic susceptibility for
complex diseases (Falconer 1967) suggests that several
genes, all of a modest impact, contribute to the genetic
susceptibility to develop or maintain complex pathologies
such as anxiety disorders. So far, a multitude of positive
ﬁndings linking genetic polymorphisms to anxiety disorder
liability has been reported (for review, Finn et al. 2003;
Gratacos et al. 2007; Hovatta and Barlow 2008), although
replication in independent cohorts often failed due to
phenotypic or genetic heterogeneity and methodological
issues (Kendler 2005; Munafo 2006).
As summarized in Table 4, several human genetic
linkage and association studies have investigated the
genetic load of GABA system pathways on the psychobi-
ology of anxiety. Positive signals for an association with
anxiety disorders and anxiety-related personality traits
have been observed for genes encoding glutamic acid
decarboxylase, the a6 and b3 subunits of the GABAA
receptor, type 1 GABAB receptor and the diazepam binding
inhibitor. These published observations, together with our
ﬁndings, may implicate a multiple system hit—theory in
the genetic underpinning of anxiety disorder as it was
recently described for the lithium-sensitive phoshatidyli-
nositol pathway in the genetic susceptibility for bipolar
disorder (Baum et al. 2008). Thus, no single genetic
polymorphism or a small set of SNPs within a component
of this neuroinhibitory pathway is sufﬁcient to trigger the
disease. However, many loci at different genes of the
GABA system, each of a small effect size, may contribute
to an individual’s disease risk. If the person’s total burden
of risk loci reaches some threshold, pathological anxiety
could develop under the inﬂuence of adverse exogenic
factors.
Conclusion
In essence, our results indicate that genetic variance in
SLC6A1 may be associated with the aetiopathogenesis of
anxiety disorders and, importantly, may modulate the
severity of panic attacks in these patients. Although this
study lacks independent conﬁrmation and further data
about the neurobiological relevance of our ﬁndings, it
supports the involvement of a dysregulation in GABAergic
Table 4 Summary of human genetic studies linking the GABA system to anxiety disorders and related personality traits
Genes Polymorphisms Phenotypes Analyses Findings References
Glutamate
decarboxylase 1
(GAD1)
2q31.1; 5 SNPS GAD, PD,
Agoraphobia,
social phobia
Case-control (589 cases,
539 patients)
P = 0.032 Hettema et al. (2006)
Glutamate
decarboxylase 2
(GAD2)
10p11; dinucleotide RP Anxiety trait
(behavioural
inhibition)
Linkage (66 pedigrees) P = 0.05 Smoller et al. (2001)
GABRA6 5q34; 1 SNP Anxiety trait
(neuroticism)
Dimensional (419
subjects)
P = 0.003 Sen et al. (2004)
GABRA6 5q34; 1 SNP PD Case-control (87
patients, 114 controls)
P = NS Kobayashi et al. (2007)
GABRA1-5,
GABRB1,
GABRB3
GABRG2
4p14-q12, 5q32–35,
15q11–13, Xq28;
(CT)n RP
PD w/o Agoraphobia Linkage (26 pedigrees) P = NS Crowe et al. (1997)
GABRB1 4p13; tetranucleotide RP PD Linkage (5 pedigrees) P = NS Schmidt et al. 1993
GABRB3 15q11-13; dinucleotide RP PTSD Dimensional (86 subjets) P = 0.0002 Feusner et al. (2001)
GABBR1 4p13; 3 SNPs PD Case–control (87
patients, 89 controls)
P = NS Sand et al. (2000)
Diazepam binding
inhibitor (DBI)
2p14.2; 1 SNP Anxiety disorders with
PA
Case–control (176
patients, 301 controls)
P = 0.032 Thoeringer et al. (2007)
GABRA c-aminobutyric acid receptor type A, alpha subunit; GABRB c-aminobutyric acid receptor type A, beta subunit; GABRG c-aminobutyric
acid receptor type A, gamma subunit; GABBR aminobutyric acid receptor type B (for further details on gene names and symbols see HUGO
Gene Nomenclature Committee, www.genenames.org), GAD generalized anxiety disorder, NS not signiﬁcant, RP repeat polymorphisms, PD
panic disorder, PA panic attacks, PTSD posttraumatic stress disorder, SNP single nucleotide polymorphism
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123circuits in pathological anxiety and highlights GAT-1 as a
promising target for the treatment of anxiety disorders and
speciﬁcally for panic symptoms. First positive clinical
studies with GAT-1 inhibitors substantiate this idea.
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